Study analysis finds Vytorin works better than Lipitor

Share this article:
Merck and Schering-Plough said Monday that new analysis of a previously released study of its jointly marketed Vytorin (ezetimibe/simvastatin) showed it was better at lowering bad cholesterol levels than Pfizer’s top-selling Lipitor (atorvastatin calcium). The study—known as Vytorin Versus Atorvastatin, or Vyva—was presented at the annual scientific meeting of the American College of Cardiology. The new analysis found that a “significantly greater” number of Vytorin users were able to lower their levels of LDL, or “bad cholesterol,” compared with those using Lipitor. Merck and Schering-Plough also said the new analysis showed Vytorin lowered levels of C-reactive protein, or CRP, and apolipoprotein B(1), or Apo B, in a greater percentage of patients than Lipitor. Both CRP and Apo B are believed to be risk markers for cardiovascular disease.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.